Application of Microbiome Management in Therapy for <i>Clostridioides difficile</i> Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents
Oral vancomycin and metronidazole, though they are the therapeutic choice for <i>Clostridioides difficile</i> infections (CDIs), also markedly disturb microbiota, leading to a prolonged loss of colonization resistance to <i>C. difficile</i> after therapy; as a result, their u...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/10/6/649 |
| _version_ | 1797532949364604928 |
|---|---|
| author | Chun-Wei Chiu Pei-Jane Tsai Ching-Chi Lee Wen-Chien Ko Yuan-Pin Hung |
| author_facet | Chun-Wei Chiu Pei-Jane Tsai Ching-Chi Lee Wen-Chien Ko Yuan-Pin Hung |
| author_sort | Chun-Wei Chiu |
| collection | DOAJ |
| description | Oral vancomycin and metronidazole, though they are the therapeutic choice for <i>Clostridioides difficile</i> infections (CDIs), also markedly disturb microbiota, leading to a prolonged loss of colonization resistance to <i>C. difficile</i> after therapy; as a result, their use is associated with a high treatment failure rate and high recurrent rate. An alternative for CDIs therapy contains the delivery of beneficial (probiotic) microorganisms into the intestinal tract to restore the microbial balance. Recently, mixture regimens containing <i>Lactobacillus</i> species, <i>Saccharomyces boulardii</i>, or <i>Clostridium butyricum</i> have been extensively studied for the prophylaxis of CDIs. Fecal microbiota transplantation (FMT), the transfer of (processed) fecal material from healthy donors to patients for treating CDIs, combined with vancomycin was recommended as the primary therapy for multiple recurrent CDIs (rCDIs). Either probiotics or FMT have been utilized extensively in preventing or treating CDIs, aiming at less disturbance in the microbiota to prevent rCDIs after therapy cessation. Otherwise, many newly developed therapeutic agents have been developed and aim to preserve microbiota during CDI treatment to prevent disease recurrence and might be useful in clinical patients with rCDIs in the future. |
| first_indexed | 2024-03-10T11:07:37Z |
| format | Article |
| id | doaj.art-b3c160fa214f473699d7b3ebaea5bad6 |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-10T11:07:37Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-b3c160fa214f473699d7b3ebaea5bad62023-11-21T21:03:46ZengMDPI AGPathogens2076-08172021-05-0110664910.3390/pathogens10060649Application of Microbiome Management in Therapy for <i>Clostridioides difficile</i> Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial AgentsChun-Wei Chiu0Pei-Jane Tsai1Ching-Chi Lee2Wen-Chien Ko3Yuan-Pin Hung4Department of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare, Tainan 700, TaiwanDepartment of Medical Laboratory Science and Biotechnology, National Cheng Kung University, Medical College, Tainan 704, TaiwanClinical Medicine Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, TaiwanDepartment of Internal Medicine, College of Medicine, National Cheng Kung University Hospital, Tainan 704, TaiwanDepartment of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare, Tainan 700, TaiwanOral vancomycin and metronidazole, though they are the therapeutic choice for <i>Clostridioides difficile</i> infections (CDIs), also markedly disturb microbiota, leading to a prolonged loss of colonization resistance to <i>C. difficile</i> after therapy; as a result, their use is associated with a high treatment failure rate and high recurrent rate. An alternative for CDIs therapy contains the delivery of beneficial (probiotic) microorganisms into the intestinal tract to restore the microbial balance. Recently, mixture regimens containing <i>Lactobacillus</i> species, <i>Saccharomyces boulardii</i>, or <i>Clostridium butyricum</i> have been extensively studied for the prophylaxis of CDIs. Fecal microbiota transplantation (FMT), the transfer of (processed) fecal material from healthy donors to patients for treating CDIs, combined with vancomycin was recommended as the primary therapy for multiple recurrent CDIs (rCDIs). Either probiotics or FMT have been utilized extensively in preventing or treating CDIs, aiming at less disturbance in the microbiota to prevent rCDIs after therapy cessation. Otherwise, many newly developed therapeutic agents have been developed and aim to preserve microbiota during CDI treatment to prevent disease recurrence and might be useful in clinical patients with rCDIs in the future.https://www.mdpi.com/2076-0817/10/6/649<i>Clostridioides difficile</i><i>Clostridioides difficile</i> infectionmicrobiomeprobioticsrecurrencefecal microbiota transplantation |
| spellingShingle | Chun-Wei Chiu Pei-Jane Tsai Ching-Chi Lee Wen-Chien Ko Yuan-Pin Hung Application of Microbiome Management in Therapy for <i>Clostridioides difficile</i> Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents Pathogens <i>Clostridioides difficile</i> <i>Clostridioides difficile</i> infection microbiome probiotics recurrence fecal microbiota transplantation |
| title | Application of Microbiome Management in Therapy for <i>Clostridioides difficile</i> Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents |
| title_full | Application of Microbiome Management in Therapy for <i>Clostridioides difficile</i> Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents |
| title_fullStr | Application of Microbiome Management in Therapy for <i>Clostridioides difficile</i> Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents |
| title_full_unstemmed | Application of Microbiome Management in Therapy for <i>Clostridioides difficile</i> Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents |
| title_short | Application of Microbiome Management in Therapy for <i>Clostridioides difficile</i> Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents |
| title_sort | application of microbiome management in therapy for i clostridioides difficile i infections from fecal microbiota transplantation to probiotics to microbiota preserving antimicrobial agents |
| topic | <i>Clostridioides difficile</i> <i>Clostridioides difficile</i> infection microbiome probiotics recurrence fecal microbiota transplantation |
| url | https://www.mdpi.com/2076-0817/10/6/649 |
| work_keys_str_mv | AT chunweichiu applicationofmicrobiomemanagementintherapyforiclostridioidesdifficileiinfectionsfromfecalmicrobiotatransplantationtoprobioticstomicrobiotapreservingantimicrobialagents AT peijanetsai applicationofmicrobiomemanagementintherapyforiclostridioidesdifficileiinfectionsfromfecalmicrobiotatransplantationtoprobioticstomicrobiotapreservingantimicrobialagents AT chingchilee applicationofmicrobiomemanagementintherapyforiclostridioidesdifficileiinfectionsfromfecalmicrobiotatransplantationtoprobioticstomicrobiotapreservingantimicrobialagents AT wenchienko applicationofmicrobiomemanagementintherapyforiclostridioidesdifficileiinfectionsfromfecalmicrobiotatransplantationtoprobioticstomicrobiotapreservingantimicrobialagents AT yuanpinhung applicationofmicrobiomemanagementintherapyforiclostridioidesdifficileiinfectionsfromfecalmicrobiotatransplantationtoprobioticstomicrobiotapreservingantimicrobialagents |